Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream

Reuters

Jul 22, 2025

Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream

Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by Wall Street Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize $(ABC.AU)$ strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553709253"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553709253\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553709253?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553709253","market":"fut","top_or_hot":-1,"title":"Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by <a href=\"https://laohu8.com/S/WSCO\">Wall Street</a> Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize <a href=\"https://laohu8.com/S/ABC.AU\">$(ABC.AU)$</a> strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-22 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by <a href=\"https://laohu8.com/S/WSCO\">Wall Street</a> Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize <a href=\"https://laohu8.com/S/ABC.AU\">$(ABC.AU)$</a> strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL1Bh3Sd:1","article_id":"2553709253","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553709253","pubTimestamp":1753186525,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aditxt, Inc.  recently highlighted the innovations of its wholly owned subsidiary, Adimune, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by Wall Street Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize  strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ADTX":"ADiTx Therapeutics"},"translate_title":"阿迪穆尼™占据中心舞台：Aditxt子公司在即将到来的直播中瞄准自身免疫性突破","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADTX":0.9},"content_text":"Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n    \n\n        Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by Wall Street Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize $(ABC.AU)$ strategy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}